Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 12/20 | 0.46 |
| ▸ | MAOB | P27338 | 12/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5222634 | 0.89 | MAOA (0.41) | MAOAMAOBMAPTCYP1A2CYP3A4 | |
| SCHEMBL5220041 | 0.87 | MAOA (0.45) | MAOAMAOBMAPTCYP1A2CYP3A4 | |
| SCHEMBL5216775 | 0.83 | MAOA (0.40) | MAOAMAOBMAPTNPC1CYP1A2 | |
| SCHEMBL5218956 | 0.78 | MAOA (0.57) | MAOAMAOBMAPTNPC1CYP1A2 | |
| SCHEMBL6712751 | 0.78 | MAPT (0.43) | MAOAMAOBMAPTNPC1CYP1A2 | |
| SCHEMBL4542129 | 0.76 | MAPT (0.41) | MAOAMAOBMAPTNPC1CYP1A2 | |
| SCHEMBL1615170 | 0.76 | MAOB (0.51) | MAOAMAOBMAPTNPC1CYP1A2 | |
| SCHEMBL12455625 | 0.75 | MAPT (0.49) | MAOAMAOBMAPTNPC1CYP1A2 | |
| SCHEMBL31730228 | 0.75 | NPC1 (0.48) | MAOAMAOBMAPTNPC1CYP1A2 | |
| SCHEMBL1254776 | 0.75 | NPC1 (0.48) | MAOAMAOBMAPTNPC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572676-A4 | HIGH SPECIFICITY ANTICANCER PHARMACOLOGICAL DRUG SYSTEM, DRUG SYNTHESIS, AND DRUG DEVELOPMENT PROCESS | WALKER CANCER RES INST INC (US) | 2007-07-25 | — | — | EP | claimed |
| EP-1572676-A2 | HIGH SPECIFICITY ANTICANCER PHARMACOLOGICAL DRUG SYSTEM, DRUG SYNTHESIS, AND DRUG DEVELOPMENT PROCESS | Walker Cancer Research Institute, Inc. (US) | 2005-09-14 | — | — | EP | claimed |
| US-6767919-B2 | 1-(N,N-DIALKYLAMINOALKYL)-4-SILYLOXYTHIOXANTHONE DERIVATIVES; ADMINISTERED IN NONTOXIC, PROTO-DRUG FORM; TIME DELAY ALLOWS FOR DIFFERENTIAL CONCENTRATION IN TARGET TISSUES OR CELLS; ACTIVATED BY DRUG | WALKER CANCER RESEARCH INSTITUTE, INC. | 2004-07-27 | — | — | US | claimed |
| WO-2004058143-A2 | HIGH SPECIFICITY ANTICANCER PHARMACOLOGICAL DRUG SYSTEM, DRUG SYNTHESIS, AND DRUG DEVELOPMENT PROCESS | WALKER CANCER RESEARCH INSTITUTE, INC. (US) | 2004-07-15 | — | — | WO | claimed |
| US-20040116508-A1 | HIGH SPECIFICITY ANTICANCER PHARMACOLOGICAL DRUG SYSTEM, DRUG SYNTHESIS, AND DRUG DEVELOPMENT PROCESS | WALKER CANCER RESEARCH INSTITUTE, INC. | 2004-06-17 | — | — | US | claimed |
| EP-1572676-A4 | HIGH SPECIFICITY ANTICANCER PHARMACOLOGICAL DRUG SYSTEM, DRUG SYNTHESIS, AND DRUG DEVELOPMENT PROCESS | WALKER CANCER RES INST INC (US) | 2007-07-25 | — | — | EP | disclosed |
| EP-1572676-A2 | HIGH SPECIFICITY ANTICANCER PHARMACOLOGICAL DRUG SYSTEM, DRUG SYNTHESIS, AND DRUG DEVELOPMENT PROCESS | Walker Cancer Research Institute, Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20040192578-A1 | High specificity anticancer drug design process | WALKER EVAN HARRIS (US) | 2004-09-30 | — | — | US | disclosed |
| US-6767919-B2 | 1-(N,N-DIALKYLAMINOALKYL)-4-SILYLOXYTHIOXANTHONE DERIVATIVES; ADMINISTERED IN NONTOXIC, PROTO-DRUG FORM; TIME DELAY ALLOWS FOR DIFFERENTIAL CONCENTRATION IN TARGET TISSUES OR CELLS; ACTIVATED BY DRUG | WALKER CANCER RESEARCH INSTITUTE, INC. | 2004-07-27 | — | — | US | disclosed |
| WO-2004058143-A2 | HIGH SPECIFICITY ANTICANCER PHARMACOLOGICAL DRUG SYSTEM, DRUG SYNTHESIS, AND DRUG DEVELOPMENT PROCESS | WALKER CANCER RESEARCH INSTITUTE, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040116508-A1 | HIGH SPECIFICITY ANTICANCER PHARMACOLOGICAL DRUG SYSTEM, DRUG SYNTHESIS, AND DRUG DEVELOPMENT PROCESS | WALKER CANCER RESEARCH INSTITUTE, INC. | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192578-A1 | High specificity anticancer drug design process | MCL1, ABCG2, TP53 | MAOA 4521/4885MAOB 4377/4885MAPT 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.